Analysts Issue Forecasts for Rocket Pharmaceuticals Inc’s Q1 2021 Earnings (NASDAQ:RCKT)

Share on StockTwits

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) – Equities research analysts at Piper Jaffray Companies issued their Q1 2021 EPS estimates for shares of Rocket Pharmaceuticals in a research note issued on Thursday, November 7th. Piper Jaffray Companies analyst T. Van. Buren expects that the biotechnology company will earn ($0.70) per share for the quarter. Piper Jaffray Companies currently has a “Overweight” rating on the stock. Piper Jaffray Companies also issued estimates for Rocket Pharmaceuticals’ Q2 2021 earnings at ($0.75) EPS and Q3 2021 earnings at ($0.80) EPS.

A number of other brokerages also recently commented on RCKT. Cowen reiterated a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Thursday. ValuEngine downgraded Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research downgraded Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. Oppenheimer reduced their price objective on Rocket Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, William Blair restated a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $28.33.

RCKT stock traded up $1.20 during trading on Friday, hitting $16.36. 171,500 shares of the company traded hands, compared to its average volume of 286,469. Rocket Pharmaceuticals has a 1 year low of $10.75 and a 1 year high of $20.79. The company has a market cap of $729.55 million, a PE ratio of -8.66 and a beta of 2.74. The company has a debt-to-equity ratio of 0.18, a current ratio of 17.48 and a quick ratio of 17.48. The stock’s 50-day simple moving average is $13.02 and its 200 day simple moving average is $14.19.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.11.

A number of large investors have recently bought and sold shares of RCKT. Lindbrook Capital LLC raised its position in Rocket Pharmaceuticals by 200.0% in the third quarter. Lindbrook Capital LLC now owns 3,000 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 2,000 shares during the period. Bank of Montreal Can purchased a new stake in Rocket Pharmaceuticals in the second quarter valued at $38,000. Tower Research Capital LLC TRC raised its position in Rocket Pharmaceuticals by 1,107.4% in the third quarter. Tower Research Capital LLC TRC now owns 4,250 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,898 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in Rocket Pharmaceuticals in the second quarter valued at $86,000. Finally, Meeder Asset Management Inc. purchased a new stake in Rocket Pharmaceuticals in the third quarter valued at $88,000. Institutional investors own 96.72% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Further Reading: How to trade on quiet period expirations

Earnings History and Estimates for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.